NASDAQ: RPHMReneo Pharmaceuticals Inc Stock
$6.04+0.47 (+8.44%)
Updated Mar 24, 2023
RPHM Price
$6.04
Fair Value Price
$8.40
Market Cap
$148.16M
52 Week Low
$1.79
52 Week High
$6.71
P/E
-3.13x
P/B
1.32x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$48.96M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
-$42M
Beta
0.83
Next Earnings
May 8, 2023
Ex-Dividend
N/A
Next Dividend
N/A
RPHM Overview
Reneo Pharmaceuticals Incorporated develops therapies for patients with rare genetic mitochondrial diseases. REN001 is a selective peroxisome proliferator-activated receptor delta agonist in (1) Phase IIb clinical trials in patients with primary mitochondrial myopathies, and (2) Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals was incorporated in 2014 and is headquartered in San Diego, CA.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RPHM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RPHM ($6.04) is undervalued by 28.06% relative to our estimate of its Fair Value price of $8.40 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
RPHM ($6.04) is significantly undervalued by 28.06% relative to our estimate of its Fair Value price of $8.40 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
RPHM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RPHM due diligence checks available for Premium users.
Be the first to know about important RPHM news, forecast changes, insider trades & much more!
RPHM News
Valuation
RPHM fair value
Fair Value of RPHM stock based on Discounted Cash Flow (DCF)
Price
$6.04
Fair Value
$8.40
Undervalued by
28.06%
RPHM ($6.04) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RPHM ($6.04) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RPHM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RPHM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.13x
Industry
17.88x
Market
21.37x
RPHM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.32x
Industry
4.89x
RPHM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RPHM's financial health
Profit margin
Revenue
$0.0
Net Income
-$13.0M
Profit Margin
0%
RPHM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$122.5M
Liabilities
$10.5M
Debt to equity
0.09
RPHM's short-term assets ($121.00M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RPHM's short-term assets ($121.00M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RPHM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.8M
Investing
-$45.4M
Financing
$97.0k
RPHM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RPHM vs Biotech Stocks
Reneo Pharmaceuticals Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.